Clik here to view.
Test might someday help spot early lung cancer
Lung cancer is the leading cancer killer in the world, and only about 15% of cases are diagnosed at an early stage, when it's most treatable.See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Tests Might Someday Help Spot Early Lung Cancer
CancerCompass: Tests Might Someday Help Spot Early Lung Cancer http://t.co/gd0An896 via @AddThis...See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Study reveals mechanism of lung-cancer drug resistance ...
COLUMBUS, Ohio New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents...
View ArticleClik here to view.
Combination of gefitinib and miRNA-inhibitor might effectively treat NSCLC -...
Combination of gefitinib and miRNA-inhibitor might effectively treat NSCLCNews-Medical.netIt also offers a new strategy for treating non-small cell lung cancer (NSCLC), which is responsible for about...
View ArticleClik here to view.
New Test Could Be Better At Detecting Lung Cancer - KETV Omaha
"It's a big deal for the grandfather of eight, who's battling terminal lung cancer. The diagnosis came in early 2008, but Whearty said he'd had symptoms at least two years earlier..."See it on...
View ArticleClik here to view.
Delays in the Diagnosis of Lung Cancer
"A common theme among people I talk with who have lung cancer is how long it took to be diagnosed. Sometimes the delays I hear about are fairly short - the specialist was busy for a week and a half...
View ArticleClik here to view.
Study identified source of crizotinib resistance in ALK-positive lung cancer...
Somatic kinase domain mutations, gene fusion and the emergence of separate oncogenic drivers are factors responsible for the observed crizotinib resistance ...See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Retreatment with erlotinib: Regain of TKI sensi... [Eur J Cancer. 2011] -...
"BACKGROUND:Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially impressive response to...
View ArticleClik here to view.
National Cancer Institute Awards Two Lung Cancer Circulating Tumor Cell (CTC)...
"Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research, personalized medicine and the molecular diagnostics of cancer, today announced that the National Cancer...
View ArticleClik here to view.
Cynvenio Awarded Two SBIR Contracts to Develop Lung Cancer Assays Using CTC...
"Cynvenio Biosystems received two $195,000 Phase I Small Business Innovation Research (SBIR) contracts from the National Cancer Institute to fund the development of blood-based lung cancer assays based...
View ArticleClik here to view.
Medical News:Radiation Gets Nod over Surgery in Early NSCLC - in Oncology,...
"Patients with severe chronic obstructive pulmonary disease and early-stage lung cancer had better 30-day survival when treated with stereotactic body radiotherapy (SBRT) instead of surgery,...
View ArticleClik here to view.
The IN VIVO Blog: Pfizer's Dolsten Sees a Bright Future for Xalkori and...
"During a fireside chat at the BIOCEO meeting in New York this week, Pfizer’s president of worldwide R&D Mikael Dolsten ranged over the company’s R&D spend (down!), FDA filings (up!), and...
View ArticleClik here to view.
Roche says fake Avastin found in Syria in 2009 - Health - Life & Style -...
Article highlights the dangers of counterfeit medicines for high priced agents in the global community.See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Study links heavy diesel exhaust to lung cancer - CTV.ca
Los Angeles TimesStudy links heavy diesel exhaust to lung cancerCTV.caAP WASHINGTON — There's new evidence that exposure to exhaust from diesel engines increases the risk of lung cancer.See it on...
View ArticleClik here to view.
Does maintenance pemetrexed maintain quality of life? : The Lancet Oncology
Does maintenance pemetrexed maintain quality of life?. By - Thomas E Stinchcombe, David Cella ([Comment] Does maintenance pemetrexed maintain quality of life?See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Lung Cancer Screening Trial Helps First Patient « VICC News ...
Kathy Leiser first heard about Vanderbilt-Ingram Cancer Center's lung cancer screening trial through a sponsorship ad on WPLN radio last summer. The Nashville office technology saleswoman and...
View ArticleClik here to view.
Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung...
"Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed...
View ArticleClik here to view.
Calallen Cancer Doctor Surprised, Upset By FDA Raid - KRIS Corpus Christi News
Cancer Doctor Surprised, Upset By FDA. South Texas Comprehensive Cancer Centers, operated by Dr.See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
New Study Questions The Effectiveness Of Avastin - Doctor Tipster
New Study Questions The Effectiveness Of Avastin. These discoveries, made by scientists at Johns Hopkins University School of Medicine, dispute the effectiveness of current treatments against cancer,...
View ArticleClik here to view.
Peregrine Pharma Cancer Drug Unmasked by Independent Review - TheStreet.com
Peregrine Pharma Cancer Drug Unmasked by Independent Review. TheStreet.com(TheStreet) --Peregrine Pharmaceuticals'(PPHM) experimental lung cancer drug bavituximab looks like a bust.See it on Scoop.it,...
View ArticleClik here to view.
Drug Resistance in Lung Cancer Treatment - dailyRx
Drug Resistance in Lung Cancer TreatmentdailyRxFuture testing for the presence of these mutations in lung cancer patients may help oncologists avoid losing valuable time when treating patients with...
View ArticleClik here to view.
2011 Highlights in Lung Cancer, by Dr. Jared Weiss, Part 1: The EGFR Axis |...
This is a great resource for obtaining a status on current treaments in lung cancer and the status of research as well.See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Lung Cancer Highlights, 2011 by Dr. Weiss, Part 2: ALK and other New...
Focus on EML4-ALK & ALK rearrangements in NSCLC, lung cancer & crizotinib (XALKORI) as targeted therapy. Also discussion of ROS-1 and crizotinib for this group.See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung...
This important article reviews the role of Exon-19 insertions as important markers of sensitivuty to EGFR-TKI therapy. These mutations are poorly described and may be missing from mutation-specific...
View ArticleClik here to view.
Extra copies of EGFR gene signal poor prognosis for vulvar cancer -...
MGH researchers report that women with vulvar carcinoma whose tumors have extra copies of the EGFR gene are at increased risk of dying from their cancer, information that could indentify patients who...
View ArticleClik here to view.
Lung Cancer at ASCO: Latest Trial Results and Emerging Therapies - Cancer...
Lung Cancer at ASCO: Latest Trial Results and Emerging TherapiesSee it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
NYT: Large lung cancer study suggests targeted treatment
The first large and comprehensive study of the genetics of a common lung cancer finds that more than half the tumors from that cancer have mutations that might be treated by new drugs that are already...
View ArticleClik here to view.
Effectively targeting KRAS in lung cancer with a MEK inhibitor
Exciting article from Sally Church reviewing a potential breakthrough in the treatment of NSCLC with KRAS mutations.See it on Scoop.it, via Lung Cancer
View ArticleClik here to view.
Molecular Targeted Agents and Biologic Therapies for Lung Ca... : Journal of...
"Tabulated below are “targeted” or novel agents that are being or have been evaluated in non-small cell lung cancer and small cell lung cancer. Only compounds that have entered clinical trials have...
View ArticleClik here to view.
Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy...
Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic...
View Article
